
Boston Scientific Corp. (NYSE:BSX) garnered two upgrades and one downgrade from analysts this week, creating a roller-coaster effect in stock prices for the medical device giant.
The company’s stock has been closing at higher and higher values all week, but slid nearly 4 percent in midday trading Friday after an analyst at wealth management service UBS downgraded the stock from buy to neutral.
Wall Street analyst Rajeev Jashnani said the stock isn’t likely to trade higher until BSX can report sustained revenue.